Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study

[1]  Richard D. Riley,et al.  A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance , 2012, Breast Cancer Research and Treatment.

[2]  K. Czene,et al.  Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement , 2012, Breast Cancer Research.

[3]  A. LaCroix,et al.  Evaluating breast cancer risk projections for Hispanic women , 2012, Breast Cancer Research and Treatment.

[4]  P. Tan,et al.  Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women , 2012, Breast Cancer Research.

[5]  C. Ãlvarez-Dardet,et al.  [Social determinants of overweight and obesity in Spain in 2006]. , 2011, Medicina clinica.

[6]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[7]  Mitchell H Gail,et al.  Personalized estimates of breast cancer risk in clinical practice and public health , 2011, Statistics in medicine.

[8]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[9]  B. Graubard,et al.  Data and trends in cancer screening in the United States , 2010, Cancer.

[10]  P. Hartge,et al.  Effect of changing breast cancer incidence rates on the calibration of the Gail model. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Ascunce,et al.  Cancer screening in Spain. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Thun,et al.  Performance of Common Genetic Variants in Breast-cancer Risk Models , 2022 .

[13]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.

[14]  C. Navarro,et al.  Recent Changes in Breast Cancer Incidence in Spain, 1980–2004 , 2009, Journal of the National Cancer Institute.

[15]  J. Cuzick,et al.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Vierkant,et al.  Assessment of the accuracy of the Gail model in women with atypical hyperplasia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Gail.  Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. , 2008, Journal of the National Cancer Institute.

[18]  G. Anderson,et al.  Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.

[19]  Eric J Feuer,et al.  The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.

[20]  J. Castilla,et al.  Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme , 2007, Journal of medical screening.

[21]  Stefano Calza,et al.  Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. , 2006, Journal of the National Cancer Institute.

[22]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.

[23]  Elia Biganzoli,et al.  A time‐dependent discrimination index for survival data , 2005, Statistics in medicine.

[24]  V Shane Pankratz,et al.  Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.

[25]  Mitchell H Gail,et al.  On criteria for evaluating models of absolute risk. , 2005, Biostatistics.

[26]  Laura Antolini,et al.  Inference on Correlated Discrimination Measures in Survival Analysis: A Nonparametric Approach , 2004 .

[27]  H. Murff,et al.  Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. , 2004, JAMA.

[28]  M. Pencina,et al.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.

[29]  S. Franceschi,et al.  Contribution of three components to individual cancer risk predicting breast cancer risk in Italy , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[30]  R. Stafford,et al.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence. , 2004, JAMA.

[31]  A Howell,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[32]  F. Clavel-Chapelon,et al.  Reproductive Factors and Breast Cancer Risk. Do They Differ According to Age at Diagnosis? , 2002, Breast Cancer Research and Treatment.

[33]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[34]  M. Zeegers,et al.  An asymptotically unbiased estimator of exposed versus non-exposed odds ratio from reported dose-response data , 2001, Statistical methods in medical research.

[35]  B Reiser,et al.  Statistical inference for the area under the receiver operating characteristic curve in the presence of random measurement error. , 2001, American journal of epidemiology.

[36]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[37]  G. Meijer.  GLOBOCAN 1: Cancer Incidence and Mortality Worldwide. , 2000 .

[38]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[39]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[40]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[41]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[42]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[43]  F. Clavel-Chapelon,et al.  Reproductive factors and breast cancer risk. Effect of age at diagnosis. , 1995, Annals of epidemiology.

[44]  E. Lustbader,et al.  Validation of a breast cancer risk assessment model in women with a positive family history. , 1994, Journal of the National Cancer Institute.

[45]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[46]  J Benichou,et al.  Estimates of absolute cause-specific risk in cohort studies. , 1990, Biometrics.

[47]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[48]  D P Byar,et al.  Estimating the population attributable risk for multiple risk factors using case-control data. , 1985, American journal of epidemiology.

[49]  T. Holford.  The analysis of rates and of survivorship using log-linear models. , 1980, Biometrics.

[50]  India,et al.  Cancer Incidence in Five Continents Vol. X , 2013 .

[51]  L. Serra-Majem,et al.  [Social determinants of overweight and obesity in Spain in 2006]. , 2011, Medicina clinica.

[52]  Q. Lê,et al.  Social Determinants of Overweight and Obesity , 2011 .

[53]  Consumer Protection,et al.  European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[55]  T. Vega Alonso,et al.  [Hormonal replacement therapy in Spain]. , 2002, Medicina clinica.

[56]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.